Put companies on watchlist
Hyperfine
ISIN: US44916K1060
WKN: A3DBAC
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Hyperfine · ISIN: US44916K1060 · Business Wire (ID: 20240828827053)
28 August 2024 10:05PM

Hyperfine, Inc. to Participate in Upcoming Investor Conferences


Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced plans to present at the upcoming H.C. Wainwright 26th Annual Global Investment Conference. Members of management are scheduled to present on Monday, September 9, 2024, at 7:00 am ET. Management will also be hosting in-person meetings at the 2024 Wells Fargo Healthcare Conference in Boston, MA on Thursday, September 5th, 2024.

A live webcast of the H.C. Wainwright event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: investors.hyperfine.io. The webcast will be archived and available for replay for at least 90 days after the event.

For more information about the Swoop® Portable MR Imaging® system, please visit hyperfine.io.

About Hyperfine, Inc. and the Swoop® Portable MR Imaging® System

Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The Swoop® system received initial U.S. Food and Drug Administration (FDA) clearance in 2020 as a portable magnetic resonance brain imaging device for producing images that display the internal structure of the head where a full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system has been approved for brain imaging in several countries, including Canada and Australia, has UKCA certification in the United Kingdom, CE certification in the European Union, and is also available in New Zealand.

The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging and data solutions. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. Traditionally, access to costly, stationary, conventional MRI technology can be inconvenient or not available when needed most. With the portable, ultra-low-field Swoop® system, Hyperfine, Inc. is redefining the neuroimaging workflow by bringing brain imaging to the patient’s bedside. For more information, visit hyperfine.io.

Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.

Contact

Investor Contact
Webb Campbell
Gilmartin Group LLC
webb@gilmartinir.com

Visual performance / price development - Hyperfine
Smart analysis and research tools can be found here.
This publication was provided by our content partner Business Wire
BusinessWire
via BusinessWire - Newsfeed
BusinessWire ©2025
BusinessWire
Contact:
101 California Street, 20th Floor San Francisco, CA, 94111 United States
+1.415.986.4422